33 results about "Corneal wound" patented technology

Histatins may be used for corneal wound healing and as a treatment for ocular surface disease in humans and other animals. For example, histatins could be included in eye drops, eye gels, ointment, glue, or embedded in (polymer) contact lenses.

The invention discloses a corneal suture nail based on a shape memory alloy. The leg part of the corneal suture nail generates a corresponding displacement due to deformation generated by the shape memory effect of the shape memory alloy, namely titanium nickel alloy, so that the corneal wounds come into contact and heal. In the invention, the used material is the titanium nickel alloy with the shape memory effect, when the ambient temperature is higher than the phase transformation temperature, the titanium nickel alloy generates martensitic phase transformation, so that the leg part of the corneal suture nail deforms and hooks the corneal tightly. The span of the corneal suture nail is 2.5mm, the length of the leg part of the corneal suture nail is 0.5mm, the radius of curvature of the waist part of the corneal suture nail is 8mm, the angle between two nail legs of the corneal suture nail is 90 degrees, the size of section of the corneal suture nail is 0.3*0.1mm<2> (the length of 0.3mm is in the thickness direction), and the leg part of the corneal suture nail is of a triangular pyramid shape with a blade to be pierced into the corneal incision conveniently.

Described herein are methods for reducing inflammation by administration of an effective amount of silk-derived proteins (SDP) or a fraction thereof to a subject having an inflammatory condition. The methods include the treatment of inflammatory conditions and wounds, including corneal wounds, comprising the topical administration of an effective amount of SDP material as described herein.

The present invention relates to pharmaceutical compositions containing lactoferrin, or fragments of it, and their use in the treatment of wounds, particularly corneal wounds. The present invention also provides a pharmaceutical composition comprising an effective amount of a polypeptide or peptidomimetic consisting essentially of the C-lobe of lactoferrin, or functionally active fragments or variants thereof.

The invention relates to the field of biological medicine, particularly discloses actin binding peptide and the purpose of the actin binding peptide. The amino acid sequence of the actin binding peptide is LKKTETQ, the synthesis difficulty and the cost are lowered, the actin binding peptide is suitable for batch production in a large scale and has a brilliant preparing function on various corneal injuries, side effects do not appear in the dosing process, and corneal wound healing and transparency recovery are benefited. Compared with a curing method through thymosin beta4, the advantages are more obvious, the side effects are small, and the actin binding peptide can be used for corneal repairing treatment.

A nanoglue is formed with one or more bioadhesive polymers, one or more dendrimers, and optionally one or more therapeutic, prophylactic, or diagnostic agents. The bioadhesive polymers and dendrimers are modified with functional groups to permit crosslinking upon one or more stimuli, e.g., ultraviolet irradiation, and form hydrogel in situ at tissue sites. In the repair of corneal wounds, the nanoglue leads to improved rate of healing with less scarring and less inflammation, compared to non-treated cornea or ones treated with sutures. Therapeutic agents can be covalently conjugated to the precursor components and be delivered to specific eye compartments, providing a more efficacious treatment formulation of ocular disorders than delivering drugs in their free forms. Methods of making and using the hydrogel and hydrogel precursor compositions are also provided.

The present invention discloses a producing method for tissue engineering cornea. The method involves using amniotic epithelial cells and amniotic stromal cells as seed cells, planting at two sides of decellularized natural corneal stroma after inducement and differentiation in vitro, forming tissue engineering cornea through organ culture in vitro. The scaffold of present invention not only resolves the problem of strong immunological rejection of heterogenetic corneal stroma, but also sustains the structure (which can restore transparency of cornea) and major components (including growth factors which could promote corneal cell growth, proliferation and differentiation) of natural cornea. Compared with the prior art, present invention has advantages of low cost, easy operation, wide range of sources and easy preservation. The said tissue engineering cornea containing live cells has certain elasticity and tenacity, and its shape, size and thickness can be changed easily. The tissue engineering cornea has very low immunogenicity. It could avoid complications caused by non-corneal material, be reconstructed by recipient cells after being transplanted in body, and be incorporated into organism rapidly to become transparent. It could be used to repair corneal wounds caused by all kinds of reasons.

The present invention relates to a composition for the treatment or prevention of a corneal injury, which comprises thymosin β4, and citric acid or its salt as active ingredients. The composition may further comprise at least one organic acid selected from acetic acid, ascorbic acid or salts thereof. The composition can maintain or increase the activity of thymosin β4 conventionally used to effectively treat wounds on the cornea, and thus, is useful as an ophthalmic formulation for treating the corneal injury.

Described herein are methods of enhancing wound healing using silk-derived proteins (SDP), including low molecular weight SDP fragments. Also described are compositions for the treatment of wounds, including corneal wounds, skin wounds, surgical incisions, burns, and skin ulcers, comprising SDP fragments, including low molecular weight SDP fragments.

The invention relates to therapeutic and cosmetic uses of calreticulin including reducing or eliminating wrinkles and / or fine lines, tissue repair and reconstruction, repairing damaged bone and / or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering from delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.

The invention provides a human keratinocyte growth factor -1 structure analogues KGF-1delta 23KGF(40S), an N end of an amino acid sequence of which lacks 23 amino acids, while the 40-bit cysteine point of which is mutated into a nonpolar amino acid. The invention also relates to a production method of the structure analogues, which carries out the fusion expression with a small ubiquitin related modifier gene mature peptide, while a fusion protein and the ubiquitin related modifier gene protease 1 co-express in the prokaryotes. In the process of fermentation expression, the ubiquitin related modifier gene protease 1 can hydrolyze the fusion protein to produce a soluble KGF-1delta 23KGF (40S). The human keratinocyte growth factor structure analogues can facilitate the proliferation of the keratinocyte cells, the growth of the hair follicle cells and inhibit the growth of the fibroblast cells, and has the functions of anti-scar, anti-fibrosis, epidermis healing facilitation and corneal wound reparation, etc.